Big Pharma Is Quietly Walking Away From the One Drug We'll All Need
The world's biggest drugmakers cut their antibiotic pipelines by 35% in five years, even as superbugs grow deadlier. A new report reveals a dangerous retreat from the drugs modern medicine can't function without.
Imagine a world where a simple cut on your finger could kill you. Where routine surgeries become life-or-death gambles. Where a child's ear infection turns fatal because no antibiotic works anymore.
That world isn't science fiction. It's the one we're sleepwalking toward, and the companies best positioned to stop it are heading for the exits.
The Numbers That Should Terrify You
The world's largest pharmaceutical companies have slashed their antibiotic pipelines by 35% in just five years. According to the 2026 Antimicrobial Resistance (AMR) Benchmark report from the Access to Medicine Foundation, the number of potential antimicrobial treatments in development at major drugmakers has dropped significantly.
Let that sink in. Superbugs are getting stronger, and the industry most capable of fighting them is doing less.
MSD cut its pipeline by a staggering 85%. Johnson & Johnson slashed theirs by 64% before abandoning its bacterial antibiotic pipeline in early 2023. Of the seven large research-based pharmaceutical companies assessed in the report, only three (GSK, Otsuka, and Shionogi) are still meaningfully investing in new antibiotics.
This isn't a gradual wind-down. It's a retreat.
Why Pharma Doesn't Want to Make the Drugs We Need Most
To understand why companies are bailing, you need to understand the bizarre economics of antibiotics. Think of it like this: imagine you spend $1.5 billion developing a new product, and then your customers are told to use it as little as possible.
That's exactly what happens with antibiotics. Doctors are supposed to prescribe new antibiotics sparingly, saving them as a last resort so bacteria don't develop resistance to them too. It's called stewardship, and it's essential for public health. But it's a nightmare for business. Low sales volume plus high development costs equals terrible returns.
Compare that to a blockbuster cancer drug or a GLP-1 weight loss med, where the goal is to get the product into as many patients as possible. If you're a pharma CEO staring at a spreadsheet, antibiotics look like a money pit next to a gold mine.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Researchers call this the "tragedy of the antibiotic commons." The drugs we most need to preserve are the ones least worth making, at least by Wall Street's math. It's the ultimate market failure.
The Kids Getting Left Behind
The pipeline problem is bad enough on its own. But zoom in on who these missing drugs are for, and the picture gets darker.
Only a small fraction of projects in the pipeline targeting WHO priority pathogens (the bacteria the World Health Organization considers the most dangerous) address children under five. And even those aren't new treatments designed for kids; they're adult-approved drugs slowly working through pediatric testing.
Meanwhile, 17 countries in sub-Saharan Africa have zero pediatric antibiotic formulations registered, despite pharmaceutical companies registering other drugs in those same markets. Companies aren't ignoring these countries entirely. They're just ignoring the antibiotics part.
This is a region where antibiotic-resistant infections hit hardest. Gram-negative bacteria (a category of especially tough, hard-to-treat bugs) cause devastating infections in children across low-income settings, and resistance rates for common pathogens like E. coli and K. pneumoniae exceed 70% in parts of Africa. Kids are dying from infections that used to be easily treatable, and the pipeline of new solutions is bone-dry.
A Slow-Moving Catastrophe With a Hard Deadline
Antimicrobial resistance already kills more than 1.14 million people directly every year, according to the GRAM Project, a collaboration between the University of Oxford and the Institute for Health Metrics and Evaluation. Millions more die from infections where resistance plays a contributing role.
By 2050, projections show direct AMR deaths rising to 1.91 million annually, a 70% increase. The broader toll, including deaths where resistance is a factor, could reach 8.22 million per year. Over the 25-year span from 2025 to 2050, cumulative deaths directly caused by resistant infections could exceed 39 million.
The economic damage is equally staggering: AMR could drain $1 to $3.4 trillion from global GDP annually by 2030 through costlier healthcare, longer hospital stays, and lost productivity.
Think of it as a slow-moving pandemic. COVID-19 crashed into our lives overnight, but AMR is creeping in year by year, building quietly in hospitals and communities, eroding the foundation that modern medicine is built on. Without effective antibiotics, organ transplants become riskier. Cancer chemotherapy becomes more dangerous. Routine C-sections become gambles.
The Scrappy Underdogs Filling the Gap
The silver lining, thin as it is, comes from smaller biotech companies. Small and medium-sized enterprises (SMEs) are now driving most of the innovation in the antibiotic space, with innovative candidates targeting critical and high-priority pathogens.
Seven late-stage innovative projects stand out. GSK's gepotidacin, recently approved for urinary tract infections and gonorrhea, is a genuine bright spot. Innoviva's zoliflodacin, also approved for gonorrhea, represents another win. Companies like Venatorx, BioVersys, and F2G are pushing forward with treatments for drug-resistant infections that disproportionately affect low- and middle-income countries.
Three of these seven late-stage projects target multidrug-resistant tuberculosis (MDR-TB), a crisis concentrated in the developing world where approximately 2 in 5 patients currently access treatment.
But small biotechs face their own problems. They have less capital, smaller manufacturing footprints, and limited ability to navigate regulatory approvals across dozens of countries. They're punching above their weight, but asking startups to solve a global health crisis that trillion-dollar companies won't touch is a shaky strategy.
Can Governments Fix What the Market Broke?
Policymakers are starting to realize that if the market won't build antibiotics, someone needs to change the market. Several creative approaches are already in motion.
The UK's NHS launched a "Netflix-style" subscription model in 2024, paying fixed annual fees to companies like Pfizer and Shionogi for access to their antibiotics regardless of how many doses are actually used. It decouples revenue from volume, which is exactly the structural fix the market needs.
The EU approved a transferable exclusivity voucher in December 2025, essentially rewarding antibiotic developers with extra patent protection they can use (or sell) for other, more profitable drugs. It's a clever workaround: make antibiotics pay by letting them subsidize something else.
In the U.S., the PASTEUR Act was reintroduced in early 2026 with bipartisan support. The legislation would create a subscription-style payment system where the federal government pays antibiotic developers between $75 million and $300 million per year per eligible product, for up to 10 years. Products would be scored on innovation, patient care improvements, and public health benefits.
Public-private partnerships like CARB-X have poured over $500 million since 2016 into early-stage antibiotic research. That funding has been critical, but it's upstream support; it helps researchers get started without guaranteeing anyone will be around to finish.
The PASTEUR Act hasn't passed yet. Prior versions have been introduced since 2020 and stalled without a floor vote every time. Advocates from the Infectious Diseases Society of America and the AMR Action Fund are pushing for swift passage, but congressional momentum remains uncertain.
The Clock Is Ticking
The overall antibiotic pipeline tells a sobering story. Since 2017, only 13 new agents have received marketing authorization globally, with a mere 2 representing new chemical classes.
For perspective: there are roughly 24 priority pathogens on the WHO's watch list. We're bringing a butter knife to a sword fight.
The 2026 AMR Benchmark report describes the situation as "thin pipeline, high stakes," and that phrase captures it perfectly. The science to fight superbugs exists. The talent exists. The need is undeniable. What's missing is a business model that makes it worthwhile for the companies with the deepest pockets to stay in the game.
Until that changes, the antibiotic pipeline will keep shrinking. And the bugs will keep evolving. They don't care about quarterly earnings, shareholder value, or congressional gridlock. They just keep adapting.
The question isn't whether we'll face an antibiotic crisis. The question is whether we'll have built the tools to fight it before the crisis arrives at our door.
Clinical & Regulatory
4 min read
Two Pharma Giants Just Crashed the Obesity Party on the Same Day
AbbVie and Regeneron dropped obesity drug data on the same day, and neither is trying to be the next Ozempic. One showed nearly 10% weight loss in just 12 weeks through a completely different mechanism; the other posted 19% weight loss with dramatically fewer side effects than Zepbound.
